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Abstract
OBJECTIVE—To evaluate the association of steroid metabolism and respiratory gene 
polymorphisms in neonates exposed to antenatal corticosteroids (ACS) with respiratory outcomes, 
small for gestational age (SGA) and response to repeat ACS.
STUDY DESIGN—This candidate gene study is a secondary analysis of women enrolled in a 
randomized controlled trial of single versus weekly courses of ACS. Nineteen single nucleotide 
polymorphisms (SNPs) in 13 steroid metabolism and respiratory function genes were evaluated. 
DNA was extracted from placenta or fetal cord serum and analyzed with TaqMan genotyping. 
Each SNP was evaluated for association via logistic regression with respiratory distress syndrome 
(RDS), CPAP/ventilator use (CPV) and SGA.
RESULTS—CRHBP, CRH and CRHR1 minor alleles were associated with an increased risk of 
SGA. HSD11B1 and SCNN1B minor alleles were associated with an increased likelihood of RDS. 
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Carriage of minor alleles in SerpinA6 was associated with an increased risk of CPV. CRH and 
CRHR1 minor alleles were associated with a decreased likelihood of CPV.
CONCLUSION—Steroid metabolism and respiratory gene SNPs are associated with respiratory 
outcomes and SGA in patients exposed to ACS. Risks for respiratory outcomes are affected by 
minor allele carriage as well as by treatment with multiple ACS.
Keywords
antenatal corticosteroids; candidate gene; respiratory distress syndrome
Introduction
Antenatal corticosteroids have long been shown to decrease the rates of neonatal respiratory 
distress syndrome and overall mortality in premature infants.1 Although several randomized 
trials have found benefits in neonatal respiratory outcomes with multiple corticosteroid 
courses, increased risks of intraventricular hemorrhage and impaired fetal growth, 
particularly head circumference, have also been reported.2,3,4 Corticosteroids are widely 
used in medicine and impact a variety of physiologic systems including the immunologic 
response, metabolism and the stress response. Genes involved in corticosteroid metabolism 
and respiratory function have been evaluated in other disease states. The impact of genetic 
variation in Corticotropin Releasing Hormone Receptor 1 (CRHR1) and lung function has 
been evaluated in asthmatics by looking at the response to inhaled corticosteroids. Evidence 
of variation in response to corticosteroids related to the genotype was identified.5,6 
Functional studies of 11 Beta Hydroxysteroid Dehydrogenase, Type 2 (HSD11B2) have 
shown corticosteroid mediated regulation of surfactant protein A altered by HSD11B2 
activity.7 Given these examples of clinical outcome associations with gene polymorphisms 
in the corticosteroid metabolism pathway, we hypothesized that genetic variation in 
corticosteroid metabolism and key respiratory function genes may play a role in adverse 
neonatal outcomes and anthropometric measurements through altered response to antenatal 
corticosteroid administration.
Evidence suggesting a genetic contribution to RDS come from both human and mouse 
studies. Lethal forms of respiratory distress syndrome (RDS) can be caused by mutations in 
pulmonary genes including: Surfactant Protein B (SFTPB), Surfactant Protein C (SFTPC) 
and ATP-Binding Cassette, Subfamily A, Member 3 (ABCA3).8,9,10 Additionally, Sftpb 
knockout mice die immediately after birth of respiratory failure.11 An intronic 
polymorphism in SFTPB has been associated with RDS in premature neonates.12 These 
studies suggest that genetic variation in key pulmonary genes may contribute to RDS 
diagnosed in the preterm infant.
Materials and Methods
This is a secondary analysis of a cohort of pregnant women enrolled at 23 0/7–31 6/7 weeks 
of gestation from a previously reported, randomized, placebo-controlled, multi-center trial of 
single versus multiple courses of antenatal corticosteroids (2 doses of Betamethasone 12mg 
IM administered 24 hours apart), conducted between March 2000 and April 2003 at 
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participating centers of the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development Maternal-Fetal Medicine Units (MFMU) Network.3 A subset of 
enrolled subjects had placental samples and fetal cord serum collected per study protocol. 
Following IRB review, this study was determined to be exempt from IRB approval due to 
de-identification of study samples and data prior to this analysis.
The objective of this secondary analysis, utilizing a candidate gene design, was to determine 
if genetic variation in fetal corticosteroid metabolism genes and key respiratory genes were 
associated with adverse neonatal outcomes and growth abnormalities evaluated by 
birthweight. The neonatal outcomes evaluated were respiratory distress syndrome (RDS), 
assisted ventilation, and small for gestational age (SGA), all of which have been associated 
with antenatal corticosteroid administration. RDS was defined as clinical features of RDS 
with the need for oxygen and respiratory support from 6 to 24 hours or more of age, an 
abnormal chest-x-ray, and either administration of a full course of surfactant or a fraction of 
inspired oxygen of at least 60%. Assisted ventilation included all neonates requiring either 
continuous positive airway pressure or intubation and ventilation (CPV) for greater than 1 
day. SGA was defined as birth weight less than the tenth percentile using the Alexander 
nomogram.13 All infants with a cord blood serum or placental sample available for analysis 
were included in this study. Exclusions from the original study were preterm premature 
rupture of the membranes, confirmed fetal lung maturity, chorioamnionitis, major fetal 
anomaly, nonreassuring fetal status, systemic corticosteroid used during the current 
pregnancy, or insulin-dependent diabetes.3 As we described in our previous publication,14 
there were 272 infants with biologic samples for DNA analysis. In this study, 215 samples 
were genotyped successfully. Placental samples were used preferentially, when both cord 
serum and placental samples were available, secondary to higher quality DNA.14 There were 
43 twin pregnancies and samples were available on both twins in 21 of these multiple 
gestations. One infant of each twin pair was randomly selected for inclusion in this analysis, 
which removed 21 infants leaving a total of 194 samples analyzed in this study, out of 594 
fetuses/infants enrolled in the original trial.3
DNA was extracted from placental samples and/or umbilical cord serum collected at the 
time of delivery. DNA was extracted from approximately 0.7 gm of fresh placental tissue or 
from 3–6, five micron sections obtained from the paraffin block using the PureGene DNA 
Purification System (Qiagen, Valencia, CA) as per the manufacturer’s protocols. DNA was 
also extracted from umbilical cord serum samples by centrifuging 250–1000 µL of cord 
serum at 10,000 × g for 10 minutes to pellet any cells in the sera. The supernatant was 
discarded and DNA was extracted with the same procedure used for placental samples.14
Candidate genes were chosen based on pathway analysis, review of the current literature and 
biological plausibility. Single nucleotide polymorphisms (SNPs) within each gene were 
selected using data from the International HapMap project (www.hapmap.org) with a minor 
allele frequency of 0.1 or greater. Each gene was minimally tagged given limited sample 
quantity for the analysis. We evaluated 19 SNPs in 13 genes that are listed in Table 1.
The samples were diluted to 2ng/ul and 1ul transferred to a 384 well plate for genotype 
analysis. Positive and negative controls were included on each 384 well plate. Allelic 
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variation was performed using the TaqMan® genotyping system (Applied Biosystems, 
Foster City, CA, US), with PCR reactions performed utilizing an ABI GeneAmp9700 
thermocycler. Allelic discrimination was performed using the Sequence Detection Systems 
2.3 software (Applied Biosystems).
Hardy-Weinberg equilibrium (HWE) exact test was performed for all markers and those with 
a p-value<0.01 were not included in further analysis. Chi-square test or Wilcoxon rank sum 
test as appropriate was used to assess differences in maternal and neonatal characteristics. 
Genotypes were included as predictors in a series of regression models that assumed an 
additive, dominant or recessive genetic pattern. The additive model assumes that having 2 
copies of the minor allele has twice the effect of having only 1 copy; the dominant model 
assumes that having at least 1 copy of the minor allele is sufficient for outcome effect and 
the recessive model assumes that 2 copies of the minor allele are needed for outcome effect. 
The genotype model reported for each identified SNP is the one with lowest p-value 
determined in logistic regression analyses. A categorical variable of race was included in our 
models as an adjustment term. An interaction effect of single versus multiple dose steroids 
and genotype was evaluated by the chi-square p-value in logistic regression model. A p-
value of <0.05 was considered to be statistically significant and no adjustments were made 
for multiple comparisons, as this was an exploratory analysis. All statistical analysis was 
performed using R (http://www.r-project.org/) and SAS software (SAS Institute, Inc, Cary, 
NC).
Results
Demographic characteristics for subjects included in this analysis are shown in Table 2. As 
summarized in Supplemental Table 1, the samples included in this study are representative 
of the samples in the original trial.3 The percentage of genotype call by marker varied from 
98.5% to 81%. Two SNPs had HWE exact test with a p-value <0.01 (Surfactant protein B 
(SFTPB rs2040349) and Corticotropin-releasing hormone (CRH rs4613981)). Both of these 
SNPs had higher rates of genotyping failures at 13% and 19% respectively. This higher rate 
of genotyping failure may be the cause of Hardy Weinberg disequilibrium. Further analysis 
of these markers was not performed due to limited available DNA.
Only one significant genetic association (CRHBP rs10062367 and SGA) was observed 
among all the recessive models. However, a more significant result was observed when the 
additive model was used for this association. Significant genetic associations with SGA, 
RDS and CPV are shown in Table 3. They were detected by either the dominant or the 
additive genetic models. The gestational age variable was evaluated for each reported SNP 
and no significant difference was observed.
An interacting effect of single course antenatal corticosteroids versus multiple course 
steroids was evaluated and significant interactions are displayed in Table 4. The referent 
cases are single course corticosteroids without minor alleles. An interacting effect was seen 
(p=0.019) with peptidase inhibitor, clade A, member 6, also known as corticosteroid binding 
globulin or SerpinA6 rs3748320 and RDS with a significantly decreased risk of RDS in the 
multiple course steroid treatment group without minor alleles (odds ratio 0.30, 95% 
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confidence interval [0.09, 0.95]) but no significant difference in risk of RDS in the multiple 
course steroid group with minor alleles (odds ratio 1.29, 95% confidence interval [0.43, 
3.91]) compared to those without a minor allele in single dose steroid group. An interacting 
effect was also noted with the epithelial sodium channel (ENaC), nonvoltage-gated 1-β gene, 
SCNN1B rs239349 and CPV with a decreased risk of CPV in the multiple course steroid 
treatment group without minor alleles (odds ratio 0.08, 95% confidence interval [0.009, 
0.66]) but no significant difference in risk in the multiple course steroid group with any 
minor allele (odds ratio 0.78, 95% confidence interval [0.28, 2.18]) compared to those 
without a minor allele in single dose steroid group.
Discussion
We performed a candidate gene analysis of steroid metabolism and respiratory function 
genes and found associations both with the genotype and respiratory outcomes as well as 
treatment effect with genotype. Previous studies have evaluated corticosteroids, genotype 
and clinical outcomes, such as effectiveness in relationship to asthma.5,6 This study is the 
first step in evaluating a novel gene-environment interaction, key respiratory genes and 
antenatal corticosteroids, on perinatal outcomes.
HSD11B1, 11 Beta Hydroxysteroid Dehydrogenase, Type 1, mediates the reversible 
conversion of cortisol to the inactive cortisone. Glucocorticoid response may be altered by 
HSD11B1 function. A role for HSD11B1 in the inflammatory response has been 
identified,15 and previous studies have suggested a role for prenatal inflammation and fetal/
neonatal lung injury.16 This may explain the relationship identified between HSD11B1 
genotype and increased risk for RDS. SerpinA6, also known as cortisol binding globulin or 
transcortin has been shown to alter cortisol binding and degradation when mutated.17 This 
finding lends biologic plausibility to genetic variation in SerpinA6 being associated with 
altered cortisol effectiveness and risk of RDS and respiratory impairment.
Low activity levels of the sodium channel, nonvoltage-gated1-β gene (SCNN1B) have been 
associated with impaired lung fluid clearance in the mouse.18 Our study found a decreased 
risk of CPAP or ventilation with multiple steroids and no minor alleles in SCNN1B which 
may relate to expression levels and clearance of amniotic fluid from the neonatal lungs that 
are related to genotype and steroid dose.
Both CRH and CRHR1 have been identified to play a role in glucocorticoid reactivity. A 
recent study of corticotropin releasing hormone knockout mice found reduced lung 
membrane glucocorticoid receptors in response to stress in the knockout mouse compared to 
wildtype.19 This may explain how a genetic variant in CRH may effect respiratory status in 
the stressful neonatal transition. Genetic variation in CRHR1 has also been associated with 
persistent pulmonary hypertension of the newborn suggesting a possible role with 
pulmonary disease in the newborn.20 Prior studies also suggest a role for the corticotrophin 
releasing hormone system regulation of birthweight and SGA which we again identified in 
our study.21,22,23
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Strengths of the study include that we assessed multiple genetic variants and their 
relationship to neonatal outcomes and antenatal corticosteroid dose and that this was done in 
the context of a large randomized, controlled trial to minimize biases of inclusion. 
Limitations to this study include that only neonates were evaluated for genetic variation and 
there may be maternal genetic variation that contributes to corticosteroid effectiveness and 
adverse perinatal outcomes. Another limitation is that samples from all neonates of enrolled 
subjects in the steroid trial were not available. It is possible there were differences between 
those who had samples available and those who did not with respect to genotypes. Likewise, 
the DNA extracted from cord blood serum and fixed placental sections provides lower 
quality and quantity DNA than that extracted from peripheral blood leukocytes. As a result, 
a lower genotype call rate was seen in this study. As documented by our generally wide 
confidence intervals, the relatively small sample size emphasizes the exploratory nature of 
this report.
The reported SNP associations may be the result of one of three findings: the reported SNP 
is itself associated with the outcome, the reported SNP is in linkage disequilibrium with the 
causal SNP which is associated with the outcome or the association reported is a false 
positive association. Association with prematurity or gestational age rather than neonatal 
outcomes is unlikely given the negative association of the SNPs with gestational age. 
Replication of these findings in a second population is important to validate these findings. 
Due to the exploratory nature of this study Bonferroni correction was not applied to the 
statistical results. If this was performed the p-value to suggest a significant association 
would be .05/17=0.003. None of our SNP associations reach this level of significance.
Debate about the use of multiple courses of antenatal corticosteroids is longstanding. While 
improved respiratory outcomes have been attributed to multiple courses of steroids, 
especially in early gestation, there continues to be concern about the effect of multiple doses 
on growth and development.3,24 If genotype plays a role in determining risk for neonatal 
outcomes or complications of antenatal steroids, then this may provide a way to stratify risk 
of a repeat course of steroids in the future. It is currently unknown if using genotype to risk 
stratify for multiple doses of antenatal corticosteroids would decrease overall neonatal 
morbidity and mortality. This study provides preliminary data and genes of interest for 
further translational as well as functional studies. In the future, these novel gene-
environment interactions may help to predict adverse perinatal outcomes and steroid 
treatment response. Ultimately, this genotype information may guide clinical care with 
regards to antenatal corticosteroid administration and safety.
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Refer to Web version on PubMed Central for supplementary material.
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Table 2








  African American 37 (38.1) 37 (38.2)
  Caucasian 35 (36.1) 36 (37.1) 0.983
  Other 25 (25.8) 24 (24.7)
Gender
  Male infant 52 (53.6) 50 (51.6) 0.774
  Female infant 45 (46.4) 47 (48.4)
Gestational age at birth (weeks) 34.9 ± 3.9 35.4 ± 3.9 0.271
Twin gestation 26 (26.8) 17 (17.5) 0.120
RDS 15 (15.5) 11 (11.3) 0.399
CPAP/Ventilation>1day 24 (24.7) 15 (15.5) 0.107
SGA 17 (17.5) 19 (19.6) 0.712
Birth weight (grams) 2347.3 ± 800.3 2405.1 ± 820.2 0.590
Data presented as mean ± SD or n (%).
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Table 3
Significant genetic association with SGA, RDS and CPV
Gene
rs number














































The referent group is without minor alleles
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